Transparency

Collaboration between our industry and healthcare professionals, healthcare organizations and patient organizations benefits patients. It is a relationship that has delivered numerous innovative medicines and treatments and changed the way many diseases impact our lives. 

Our industry, healthcare pro¬≠fessionals, healthcare organizations and patient organizations collaborate in a range of activities in the fields of clinical research, sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway. Bringing greater transparency to this already well-regulated, vital relationship is about building the basis for collaboration in the future.

Society has increasingly high expectations for transparency, in particular in the healthcare sector. At Takeda, we want to ensure we meet those expectations going forward.

Takeda is also participating in this initiative for the following reasons:

    1. Behaving ethically, honestly and transparently constitutes the essence of Takeda-ism, our company’s philosophy for almost 240 years.
    2. At Takeda, improving patients' quality of life is embedded in our daily work. We are committed to being fully transparent with regards to the relationships we have with healthcare professionals, healthcare organizations and patient organizations, who are helping us to meet this objective.
    3. We are confident that divulging transfers of value will finally lead to clear standards as well as to more transparent commercial practices, which in turn will lead to optimal protection of all parties and to the public's greater trust with regards to our interactions.

Disclosure for healthcare professionals, healthcare organizations and patient organizations in Belgium 

The disclosure of transfers of value to Belgian healthcare professionals, healthcare organizations and patient organizations is regulated by the Belgian Sunshine Act of 2017. All pharmaceutical and medical devices companies use www.betransparent.be as a common platform to disclose their financial remunerations and the contributions to the costs of scientific meetings offered to healthcare professionals, healthcare organizations and patient organizations.

More information is available at http://www.betransparent.be/

Methodological note

Disclosure for healthcare professionals and healthcare organizations in the Grand Duchy of Luxembourg

As for Luxembourg, all companies that are a member of APL (Association Pharmaceutique Luxembourgeoise) must disclose their financial remunerations and contributions to the costs of scientific meetings offered to healthcare professionals and healthcare organizations. In 2017, Takeda Belgium had no transfers of value to healthcare professionals and healthcare organisations having their primary address of practice in Luxembourg. In 2018, Takeda Belgium had the following transfers of value with healthcare professionals and institutions in Luxembourg:

Supported in 2018

Patient Organizations in Belgium

Each pharmaceutical company must make available to the public once a year a list of Belgian patient organizations to which it provided support during the past calendar years.

List of supported Patient Organizations

Supported in 2014-2015
Supported in 2016
Supported in 2017 (see http://www.betransparent.be/)